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Abstract
Background: Acute kidney injury (AKI) is independently associated with the development of chronic kidney
disease, endstage kidney disease and increased all-cause and cardiovascular-specific mortality. The severity of the
renal insult and the development of multiple AKI episodes increase the risk of occurrence of these outcomes.
Despite these long-term effects, only a minority of patients receive nephrologist follow up after an episode of AKI;
those that do may have improved outcomes. Furthermore, relatively simple quality improvement strategies have
the potential to change this status quo.
Methods: On this background, a working group of the 15th Acute Dialysis Quality Initiative (ADQI) conference
applied the consensus-building process informed by review of English language articles identified through PubMed
search to address questions related to the opportunities, methodological requirements and barriers for longitudinal
follow-up of patients with AKI in the era of electronic health records and Big Data.
Results: Four consensus statements answering the key questions identified by the working group are developed.
Conclusions: We have identified minimal data elements and potential data sources necessary to trace the natural
history of patients from onset of AKI to long-term outcome. Minimum infrastructure and key barriers to achieving
these goals are outlined together with proposed solutions.
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Abrégé
Contexte motivant la revue: L’insuffisance rénale aigüe (IRA) est associée de manière indépendante à l’évolution
de l’état de santé du patient vers l’insuffisance rénale chronique (IRC), l’insuffisance rénale terminale (IRT) et à
l’augmentation de la mortalité due à des complications, incluant des événements cardiovasculaires. Le risque d’une
aggravation de la maladie vers ces événements indésirables est augmenté par la sévérité et par la récurrence des
épisodes d’IRA. Malgré cette possibilité d’évolution défavorable à long terme, seulement une minorité de patients
bénéficie d’un suivi par un néphrologue à la suite d’un épisode d’IRA, et dans le cas de ces patients, un meilleur
pronostic pourrait être envisagé. Qui plus est, de simples stratégies d’amélioration dans la qualité du suivi
pourraient changer la situation.
Méthodologie et sources de l’information: Lors du 15e Congrès de l’Acute Dialysis Quality Initiative (ADQI), un
groupe de travail a mis en application un processus de concertation à la suite du passage en revue d’articles
publiés en anglais sur PubMed. Les paramètres de recherche visaient à répondre à des questions concernant le
bien-fondé, les exigences méthodologiques et les obstacles associés à un suivi longitudinal des patients souffrant
d’IRA en cette ère de dossiers médicaux électroniques et de mégadonnées.
Résultats: Le groupe de travail a rédigé quatre déclarations consensuelles qui répondaient aux paramètres de
recherche mentionnés, elles sont discutées dans la présente revue.
Limites de l’étude: Les auteurs n’ont pas procédé à une revue formelle et systématique de la littérature sur le
sujet.
Conclusions: Cette revue a rendu possible l’identification de données de base et de sources potentielles de
données qui permettraient de suivre l’évolution naturelle de la maladie chez les patients, des premiers épisodes
d’IRA jusqu’aux possibles complications ou événements indésirables à long terme. Les infrastructures minimales
requises et les principaux obstacles à l’atteinte de cet objectif sont exposés conjointement avec les solutions
proposées.
Background
There is increasing concern as to the long-term
consequences of patients with acute kidney injury
(AKI). Adverse outcomes reported in survivors of
AKI include an increased risk of Cchronic kidney
disease (CKD) onset and progression and death
from cardiovascular disease and from all causes [1–
12]. Experimental data show similarities between
the pathological processes that drive CKD progres-
sion and those that occur following an episode of
AKI [13, 14]. AKI and CKD may best be viewed as
inter-related syndromes with AKI leading to CKD
and CKD strongly predisposing to the development
of AKI [15]. AKI has also been linked to increased
long-term risk of cardiovascular diseases [8, 16–19],
stroke [20], infection [21] and fracture [22]. Despite
these long-term effects, only a minority of patients
receive follow up by a nephrologist after an episode
of AKI; observational studies suggest that those
that do may have improved outcomes compared
with those who do not [23, 24]. Relatively simple
quality improvement strategies have the potential to
change this status quo [25]. On this background, a
working group of the 15th Acute Dialysis Quality
Initiative (ADQI) conference sought to address the
following four questions:
Question 1: What would be the essential components
necessary to track patients following an episode of
AKI?
Question 2: What data elements and sources would be
ideally needed to trace the natural history of patients
from onset of AKI to long-term outcome?
Question 3: What would be the minimum
infrastructure needs and support to enable data
acquisition, compilation, storage, analysis and display
for each purpose?
Question 4: What are the key barriers to integrating
these data sources across a common syndrome and
tracking for longer term complications?
Methods
The 15th ADQI Consensus Conference Chairs convened
a diverse panel representing relevant disciplines (i.e.,
nephrology, critical care, pediatrics, pharmacy, epidemi-
ology, health services research, biostatistics, bioinformat-
ics and data analytics) from five countries from North
America and Europe around the theme of “Acute Kidney
Injury in the Era of Big Data” for a 2-day consensus con-
ference in Banff, Canada on September 6–8, 2015. This
consensus meeting followed the established ADQI
process, as previously described [26]. The broad object-
ive of ADQI is to provide expert-based statements and
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interpretation of current knowledge for use by clinicians
according to professional judgment and identify evidence-
care gaps to establish research priorities. From this group,
our work group was asked to examine the longitudinal fol-
low up of AKI in the era of Big Data. We applied the
consensus-building process informed by review of English
language articles identified through PubMed search by
working group members. We used search terms acute kid-
ney injury, longitudinal data, long-term follow up, big data
and data integration. We did not use a formal systematic
review process. Group members performed an objective
scientific review of the identified literature, developing a
consensus of opinion, with evidence where possible, to
distil current literature and articulate a research agenda to
address important unanswered questions. A glossary of
terms used is included in Table 1.
Results
Question 1: What would be the essential components
necessary to track patients following an episode of AKI?
Consensus statement 1A
 Short and long-term outcomes following an episode
of AKI should be tracked at both patient and popu-
lation levels to allow appropriate patient follow up
and management while concurrently enabling data
capture on the burden and outcomes of AKI.
Consensus statement 1B
 Patient level data needs to be sufficiently granular to
inform clinical diagnosis, management and processes
of care. Population level data may be collected
periodically from different sources and should link
all AKI episodes to relevant kidney health and
overall long-term outcomes.
Tracking the outcomes of patients who have sustained
AKI should be a powerful mechanism in improving stan-
dards of care, with the potential to effect change through
a variety of means. The process can be considered at in-
dividual patient or at population levels; a patient-centred
approach must take account of the fact that nephrologist
follow up after an episode of AKI often does not occur
in current practice [23]. In part, this may reflect a lack
of awareness amongst patients that they had developed
AKI, and among providers for the need for specific fol-
low up, thereby constraining subsequent patient-driven
health care encounters. The primary aim of improved
patient-level tracking would be to educate patients on
the importance of kidney health and to allow providers
to deliver supportive renal care to patients in a more
systematic way. Justification for this approach is pro-
vided by the expert onion of ADQI members and limited
observational studies showing that focused follow up
with a nephrologist may improve outcomes, by reducing
the risk of recurrent AKI [24]. In tandem, improving
identification and tracking of AKI episodes at a popula-
tion level would advance the measurement of trends in
the prevalence of AKI and its outcomes. Such ap-
proaches would move away from problems inherent with
utilization of administrative codes for case finding (in
particular a lack of sensitivity [27]) and aim to be inclu-
sive of all AKI episodes, with subsequent enrichment by
linkage to other data sources. This would allow descrip-
tions of the burden of AKI across health care systems,
and may lead to descriptions of the patient characteris-
tics that do and do not benefit from specific follow up,
or who are likely to benefit from emerging therapies.
Opportunities for organisational-level quality improve-
ment would also result (e.g., benchmarking) and this ap-
proach may even provide the basis for registry-based
clinical trials [28]. Such outputs from population level
data analysis could then feed back into patient level care
by informing the refinement of care pathways and
prognosis.
An expanding literature showing the diversity of ad-
verse outcomes associated with AKI means that the na-
ture of outcomes to be measured requires specific
consideration (Table 2). As well as renal outcomes (renal
function, albuminuria and requirement for renal replace-
ment therapy, RRT), systemic health consequences such
as cardiovascular events and even increased rates of in-
fection and fractures are relevant [8, 16, 18–22]. Further-
more symptom burden, quality of life and functional
status are the least studied outcomes although arguably
the most important from a patient’s point of view. Each
will have different measurement requirements, varying
sources from which data may be collected and require
different timeframes for follow up (Fig. 1). For example,
AKI may result in end stage kidney disease (ESKD) re-
quiring dialysis at any time-point following its onset,
whereas cardiovascular consequences are unlikely to
occur until year(s) after.
On a patient level, the individual clinical situation will
dictate how soon and how often a patient requires follow
up after an AKI episode, but follow up and subsequent
utilization of health care will ultimately be determined
by patients’ choices and behaviour. This will dictate the
frequency of data collection and even whether this hap-
pens at all. As well as targeting improved follow-up rates
(e.g., by empowering patients to take interest in their
kidney health), the precision and level of detail in clinical
records is also important [29]. An accurate summary of
the AKI episode in discharge documentation is a key
element, transferring information to primary care and
supporting better patient and provider awareness. Infor-
mation pertaining to the when, where and why the
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Table 1 Glossary of terms
Variable Definition Comments
Electronic Health
Record (EHR)
The Electronic Health Record is a longitudinal electronic record of patient
health information generated by one or more encounters in any care
delivery setting. Included in this information are patient demographics,
progress notes, problems, medications, vital signs, past medical history,
immunizations, laboratory data and radiology reports. The EHR has the
ability to generate a complete record of a clinical patient encounter, as
well as supporting other care-related activities directly or indirectly via
interface, including evidence-based decision support, quality manage-
ment and outcomes reporting [31].
EHR serve as one source of data from which pertinent
health information can be obtained. However, EHR are
not ubiquitous and may result in incomplete data
particularly as patients transition from one location to
another.
Acute Kidney
Injury (AKI)
Evidence of an acute decline in kidney function characterized by an
elevation in serum creatinine or reduction in urine output over a short
interval of 48 h to 7 days [36]. Requires documentation of a
measurable change in renal function in relation to a reference point.
The time of diagnosis, maximum stage reached, clinical
features (oliguric or not) and should be recorded. If
ancillary criteria are used e.g. decline in creatinine these
should be identified.
AKI Episode A discrete time period recognized with a starting point when
diagnostic criteria are present and ending when there is evidence of
improvement in renal function to meet criteria of recovery. Repeat
episodes should be identified by evidence of a new decline in renal
function following an improvement in renal function
It is often difficult to determine exact start and end
points of an AKI episode when creatinine and urine
output are fluctuating. Criteria for classifying discrete
episodes of AKI need to be developed.
AKI Follow-up Assessment of clinical and lab data at specific intervals following an
AKI episode. Follow up should determine the level of general heath,
level of renal function, consequences of the AKI on target organs and
functional status and assess modifiable factors influencing outcomes.
Specific interventions to improve recovery should be considered at
each follow up visit.
Data recording should distinguish single from multiple
episodes that may be contiguous or separated in time.
Analysis of the trajectory of serum creatinine changes
could be used to track individual episodes. An electronic
“tag” should be placed in patients record identifying the
index episode to enable them being recognized as high
risk for subsequent events.
Minimal Data set Set of variables that specifies the common data elements (CDE) that
would be extracted at different time points after an episode of AKI
(and then could be supplemented by additional data items).
Core data elements should include: when the AKI
episode occurred, location, etiology, associated events,
key features in management, course, consequences and
outcomes). The frequency of recording would be
defined by best practices to allow timely interventions at
patient centric levels. This minimum dataset would be
the basis for both patient centric and population level
tracking across geographic areas or jurisdictions.
Unique patient
identifiers (UPI)
A system that assigns individuals a unique number (the healthcare
version of a Social Security Number) as a tool for patient identification
across the different health care systems.
Not available in all countries and settings.
Blue Button
Initiative
A system allowing patients and consumers access to their health
records electronically through the “Blue Button” mechanism which
allows consumers to take download and use their own health
information.
Blue Button originated at the Veteran’s Administration as
a symbol on its patient portal that beneficiaries could
click to securely download their own health record
electronically. Since then the Blue Button has spread
beyond VA to other to more than 450 government and
the private sector organizations making personal health
data available to Americans.
SNOMED The Systematized Nomenclature of Medicine is a systematic, collection
of medical terms amenable for computer processing. It provides codes,
terms, synonyms and definitions which cover anatomy, diseases,
findings, procedures, microorganisms, substances, etc.
Interoperability The ability of a system to exchange electronic health information with
and use electronic health information from other systems without
special effort on the part of the user. Interoperability is made possible
by the implementation of standards.
http://www.ieee.org/publications_standards/index.html
Renal functional
recovery from
AKI
Evidence of improvement in renal function to a level close to the
reference point. There are variable definitions of complete and partial
recovery in different studies [59, 60]
Determining recovery is often difficult as there may be
inadequate follow up of clinical and lab data as patients
may be seen in different locations under different
providers and systems. This is much easier when patients
are cared for in a single health care system with shared
data (e.g Veterans Affairs medical centres in the US or UK
NHS)
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episode of AKI occurred should be recorded, as well as
how it was managed. Follow-up requirements should be
specified (including clinic appointments, clinical decision
support on timing of renal function checks and commu-
nicating medication plans) and this will also provide ref-
erence information for subsequent hospital based
encounters. In the UK, this has been designated a prior-
ity, with commissioning policy shaped to target improve-
ments in this area [30]. In time, improved granularity of
patient-level data would not only aid clinical care but
also serve to improve the quality of population-level data
collection.
In the US, the American Recovery and Reinvestment
Act and the Health Information Technology for Eco-
nomic and Clinical Health Act have driven nationwide
uptake and usage of electronic health records (EHR).
Ideally, the EHR should provide the solution to tracking
AKI outcomes, as per the Health Information Manage-
ment Systems Society definition (Table 1) [31]. However,
there are several factors that mean that this is not a
current or complete solution. Firstly, many of EHR in
current usage are fragmented, relying on a large number
of different platforms (e.g., admission, discharge and
transfer, computer-based provider order entry, clinical
decision support system, laboratory information system
(LIMS) and imaging archiving and communication sys-
tem) so that patient data are not always linked [32]. A
number of concerns have been raised around injudicious
use of erroneous, miscoded, fragmented and incomplete
data from EHR, recognizing that the quality of clinician-
entered data can contribute to this [29]. The use of EHR
is not ubiquitous, even in developed countries, thereby
limiting the capture of certain types of data. Further-
more, the integration of EHR outside individual institu-
tions or organizations does not commonly exist. It can
also be a challenge to identify the pertinent data from
within the wealth of data contained within the EHR.
Data extracts must select the most relevant; one model
would be to define a minimal dataset that specifies the
common data elements (CDE) that would be extracted
at different time points after an episode of AKI (and
then could be supplemented by additional data items).
This minimum dataset would be the basis for both
patient-centred and population-level tracking across
geographic areas or jurisdictions.
Question 2: What data elements and sources would be
ideally needed to trace the natural history of patients
from onset of AKI to long-term outcome?
Consensus statement 2A
 Methodology to detect and define an episode of AKI
must be standardised (and based on current
diagnostic criteria) if data are to be objectively
combined from multiple sources and locations.
Consensus statement 2B
 For both patient and population tracking the patient
should be the unit of observation.
Consensus statement 2C
 Relevant clinical information pertaining to an
episode of AKI should be included in a patient’s
health care encounter (including occurrence and
stage of AKI as well as a follow-up plan). As a mini-
mum follow-up requirement, renal function and al-
buminuria should be checked within three months
of an AKI encounter (as per KDIGO guidelines).
Despite the widespread acceptance of international
consensus criteria for AKI, it is still possible to introduce
considerable variation when applying these in clinical
practice. A particular challenge is selection of an individ-
ual’s baseline or reference serum creatinine, with
different methodologies producing varied diagnostic
thresholds [33]. It can be particularly difficult in those
patients with no previous serum creatinine results [34,
35]. Therefore, a core requirement is that a standardised
approach is adopted for detecting AKI if data are to be
combined from different sources and across health care
locations. Failure to do so will result in invalid compari-
sons between groups of patients in whom AKI has been
detected in different ways. Not only must the onset of
AKI be defined, but also what constitutes an ‘episode’ of
AKI (Table 1). However, even with a standardised detec-
tion method, collection of data that indicates the onset
of AKI can occur at different levels, ranging from indi-
vidual laboratory results indicating AKI, to episodes of
AKI (both of which may occur singly or multiply for an
Table 1 Glossary of terms (Continued)
Mortality Documentation of death, cause, contributing factors and time to death
from onset of AKI.
This endpoint should be measured at several time points
from AKI diagnosis but at a minimum at hospital
discharge and at 90 days post AKI.
Chronic kidney
Disease (CKD)
Status
State of kidney health prior to development of AKI based on historical
data.
Consistency in determining and recording CKD stage is
necessary. We recommend using consensus staging
criteria and validated equation to calculate estimated
glomerular filtration rate.
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Table 2 Possible outcome measures for use in tracking episodes of AKI
Entity resolution Initial encounter Subsequent encounters
Kidney Health Overall health Kidney Health Overall health
Population Name
Unique identifier
Gender
Date of birth
AKI detection results/tag.
Serum creatinine measurements
(baseline, during AKI and recovery).
ICD
codesComorbiditiesComplicationsResource
utilization e.g. length of stay, critical care
admission.
All subsequent AKI episodes,
stages and timing.
eGFR.
Albuminuria.
CKD stage.
Need for RRT.
Re-hospitalization.
New diagnoses, ICD codes:
CV events, cancer, infection, fracture,
MAKE, MARCE.
Time and cause of death.
Patient Name
Unique identifier
Sex
Date of birth
AKI detection results/tagAKI stage,
duration and settingAKI
etiologyNeed for acute
RRTNephrology consult
Setting of AKI, exposures and
co-existing illness.
Blood pressure.
Procedures.
eGFR.Albuminuria.
CKD stage.
Need for RRT.
Blood pressure.
Comorbidities.
Complications.
Quality of life/dependency.
Management Name
Unique identifier
Gender
Date of birth
Treatment given for AKI.
AKI follow up plans.
Medications.
Discharge quality indicators.
Education (including patient).
Medications (including those stopped/
temporarily suspended).Frailty measures.
Patient reported outcomes and symptoms.
CKD care.
Secondary prevention of AKI episodes.
Medications.
Functional recovery.
Cardiovascular risk.
Frailty measures.
Patient reported outcomes and symptoms.
Research Biomarkers. Specific therapies.Improved methods of
capturing patient reported data.
Therapies to facilitate recovery.Use of
biomarkers to predict risk/recovery.
Therapies to improve systemic outcomes.
AKI acute kidney injury, ICD International Classification of Diseases, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, RRT renal replacement therapy, MAKE major adverse kidney events, MARCE
major adverse renal and cardiovascular events
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individual) through to data collection on a patient level.
As multiple episodes of AKI in an individual may exert
cumulative effects [9], and because the majority of out-
comes (such as mortality, CKD progression, cardiovas-
cular events) are measured in an individual, the primary
method of tracking outcomes should be at a patient level
(i.e. the patient as the unit of observation). However, it is
important to capture occurrence and timing of multiple
AKI episodes as some analyses may need to be per-
formed at this level (e.g., short term consequences of an
AKI episode).
This methodology aligns with a concept of applying a
‘tag’ to patients’ medical records once AKI has been de-
tected (incidence), which then triggers follow up at both
patient and population levels (the location and nature of
this tag may vary depending on local capability, but
would have to be sufficiently apparent so it would be
useful for clinical practice). Timing of the index AKI epi-
sode would be used as the reference for subsequent out-
comes, including recurrent episodes of AKI. A
minimum dataset should be captured for each patient to
track post-AKI outcomes. The dataset would need to be
able to be collected at different longitudinal time points,
and identify both the patient and occurrence of subse-
quent events. At its most basic, this would include a
population specific unique patient identifier(s), alongside
an assessment of renal function (serum creatinine,
eGFR, albuminuria or urinalysis, subsequent AKI detec-
tion results, need for RRT), each with a date and time
stamp. In terms of minimum requirement for individual
patient follow up, in the absence of evidence to the con-
trary we support the KDIGO recommendation that all
patients who have sustained AKI should have renal func-
tion and albuminuria assessed within three months [36].
This also provides a process measure that may be appro-
priate as a clinical quality standard.
A more comprehensive dataset may include other sys-
temic outcomes (physiological parameters such as blood
pressure, or systemic consequences such as cardiovascu-
lar events) although an alternative approach would ex-
tract and retrospectively link this type of data from
other sources, particularly those that are binary occur-
rences. Longitudinal prescribing information also would
have value. Table 2 summarises potential outcomes mea-
sures at patient and population levels, stratified into po-
tential ease or difficulty of collection at the present time.
There are also some technical considerations including
the need for methods to deal with the use of different
units of measurement for serum creatinine (μmol/L ver-
sus mg/dL), so that conversion and merging of data are
possible. Precision in defining data fields is also essential
and the use of the standardized computer nomenclature
(Systematized Nomenclature of Medicine (SNOMED))
to reduce inconsistency in information capture and to
facilitate interchange of information across EHR is crit-
ical [37].
If a core dataset is then to be enriched by linkage, the
other data sources that may be utilised are multiple and
Fig. 1 Diagram of data collection opportunities across the acute kidney injury patient pathway. Reproduced with permission from ADQI
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varied. As previously described, it is possible classify
these into administrative data, clinical data and patient-
collected data [38], see Table 3. This then allows a
patient’s journey to be described in parallel with the lo-
cations and time points at which they may subsequently
access healthcare and the multiple data sources that
document encounters. These healthcare utilisation epi-
sodes therefore form opportunities from which outcome
data can be measured. We have attempted to demon-
strate this in Fig. 1; the patient remains at the centre of
both individual and population level approaches.
Question 3: What would be the minimum infrastructure
needs and support to enable data acquisition,
compilation, storage, analysis and display for each
purpose?
Consensus statement 3A
 A first episode of AKI should add an AKI identifier
(tag) to the patient record that would allow
subsequent identification of the episode that would
enable follow up. Inclusion of a population-based
unique patient identifier within the patient record
will facilitate database linkage and avoid duplication
of patient medical records.
Consensus statement 3B
 Patients who have sustained an episode of AKI
should be educated about the diagnosis and follow
up arrangements discussed with them.
 Providers responsible for patient care should be
informed of the patients AKI episode and need for
follow up at specific intervals.
We consider the first episode of AKI as a sentinel
event that initiates “tagging” of patient’s record with AKI
diagnosis to prompt healthcare provider to initiate longi-
tudinal follow-up. The process may be as simple as
addition of appropriate diagnostic codes to problem list
and discharge summary within EHR. Several observa-
tional studies have reported low prevalence of reported
AKI diagnoses in discharge summaries [1, 39–41] even
when AKI diagnosis was ascertained with electronic
alerts. More comprehensive approach would require def-
inition of common data elements (CDE) necessary to
Table 3 Types of data that could be utilised to track AKI (adapted from Deeny et al [38])
Data type Definition Characteristics Examples
Administrative
data
Data collected as part of the routine
administration of healthcare, for example
reimbursement and contracting.
Records of attendances, procedures and
diagnoses entered manually into the
administration system for a hospital or
other healthcare organization and then
collated at regional or national level. Little
or no patient or clinician review; no data
on severity of illness.
Hospital episode statistics (England): Clinical
coders review patients’ notes, and assign
and input codes following discharge. These
codes are used within a grouper algorithm
to calculate the payment owed to the care
provider. Veterans administration databases:
Data from health care episodes within the
VA system for both in-patient and out-
patient treatment.
Clinical data Data collected by healthcare workers to
provide diagnosis and treatment as part
of clinical care. These data might arise
from the patient (for example, reports of
symptoms) but are recorded by the
clinician.
Electronic medical record of patient
diagnoses and treatment. Results of
laboratory tests. Compared with
administrative data, less standardized in
terms of the codes used and less likely to
be collated at regional and national levels.
Electronic medical record: More than 90 %
of primary care doctors reported using the
Electronic Medical Record (EHR) in Australia,
the Netherlands, New Zealand, Norway and
the UK in 2012. In the US, the American
Recovery and Reinvestment Act and the
Health Information Technology for
Economic and Clinical Health Act have
driven nationwide uptake and usage of
electronic health records (EHR).
Patient
generated
data
Data requested by the clinician or
healthcare system and reported directly
by the patient to monitor patient health,
as well as data that the individual
decides to record autonomously without
the direct involvement of a health care
practitioner.
Data collected by the patient on clinical
metrics (eg, blood pressure), symptoms or
patient reported outcomes; also symptoms
and treatment recorded by the patient
outside the ‘traditional’ healthcare system
structures.
Examples include telehealth (e.g. for heart
failure patients), UK (Renal) PatientView that
allows patients to upload blood pressure,
weight and glucose measurements (https://
www.patientview.org), Patients Like Me an
online quantitative personal research
platform (http://www.patientslikeme.com),
and individual and patient activity on social
media.
Machine
generated
data
Data automatically generated by a
computer process, sensor etc. to monitor
staff or patient behavior passively.
Record of individual behavior as generated
by interaction with machines. The nature of
the data recorded is determined by the
technology used and substantial processing
is typically required to interpret it
Telecare sensors: Telecare aims for remote,
passive and automatic monitoring of
behavior within the home, for example for
frail older people.
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capture AKI episode. The development of CDE requires
a standardized process for structured data capture, such
as definition and capture of relevant data elements into
templates that can be automatically populated from an
EHR and a standard way to access, display and store the
data. The CDE would act as a template that can be inte-
grated in different EHR platforms and transmitted and
shared among healthcare providers and organizations.
The Office of the National Coordinator for Health In-
formation Technology (ONC), in partnership with Na-
tional Library of Medicine and Agency for Healthcare
Research and Quality has already recognized importance
of structured data capture for patient-centered integra-
tion of the EHR into other parts of the learning health
care system such as research consortia, registries and
public health agencies. Among others, the Standards and
Interoperability Framework Initiative [42] has resulted in
development of CDAs for patient-centered outcomes
reporting [43] and the common formats for safety
reporting [44]. The interest of multiple stakeholders in-
volved in these initiatives needs to be engaged in under-
standing the importance of defining common data
elements for both acute and chronic kidney disease from
both patient and public health perspective. Engagement
of representatives from professional societies such as
American Society of Nephrology, International Society
of Nephrology, National Kidney Foundation and Society
of Critical Care Medicine, is necessary to ensure uniform
and standards. The recent position paper by National
Kidney Disease Education Program outlines use of EHR
for tracking in of CKD and provides excellent framework
for expanding the issue to AKI patients [45].
In United States, the lack of unique patient identifiers
(UPI) and current state of health information technology
(IT) with inadequate EHR interoperability between dif-
ferent hospital systems, outpatient healthcare providers
and laboratory services impose major obstacle for longi-
tudinal follow-up after the initial AKI episode. The idea
behind UPI is that system would allow integration of
care delivery for individual patient across entire health
care delivery system. The lack of such system impose
major barriers in tracking disease progression for condi-
tions for which awareness in society, among patients and
healthcare providers is low, such as kidney disease and
sepsis. Both AKI and sepsis demonstrate recidivism, can
occur over time in different settings (hospital or com-
munity) and their recurrence can lead to development of
chronic conditions affecting different organs [7, 9, 10].
The implementation of a national UPI system that as-
signs individuals a unique number (the healthcare ver-
sion of a Social Security Number) has been debated as a
tool for patient identification across the different health
care systems in United States. In United Kingdom,
Canada, Australia and New Zealand such systems are
already in place. In United Kingdom the NHS number
has served this purpose since 2009 [46]. Healthcare
identifiers, unique 16 digit numbers assigned to individ-
ual patient, healthcare provider and healthcare organiza-
tions, are the building block for eHealth in Australia
[47].
The need for the improvement in existing health IT
infrastructure to support EHR interoperability is identi-
fied as the key strategic goal in the recently released
Federal Health IT Strategic Plan 2015-2020 [48]. The ad-
vancement of person-centered health and wellness
through the use of technology and health information is
set as the main strategic national goal. The key element
of the plan is development of the roadmap for EHR
interoperability and advancement of technical standards
to assure secure and interoperable health IT. Enabling
structured data capture within EHR is poised to be a
critical way to integrate EHR data into a variety of health
services and clinical research activities and will consti-
tute the important aspect of health IT development in
the next 5 years that can be used as leverage for devel-
opment of standardized longitudinal follow-up for AKI.
Question 4: What are the key barriers to integrating these
data sources across a common syndrome and tracking for
longer term complications?
Consensus statement 4
 Multiple barriers to integrating data sources
currently exist at patient, organizational and
national levels.
 Strategies to tackle these barriers need to be
developed and should include improvements in
linkage between currently fragmented health record
systems, and facilitating patient ownership of
relevant medical information.
Patients who develop AKI are often cared for by
different providers during an episode than those who
will follow them subsequently, resulting in fragmenta-
tion of care. This is further compounded by differ-
ences in the nature and frequency of data that is
recorded in the inpatient and outpatient setting. For
instance while an EHR may be available in a hospital,
when the patient is transferred to a skilled nursing fa-
cility only paper records maybe utilized and the lab
studies would not be available. Strategies to scan and
upload paper records into EHR are one possible solu-
tion to tackle this problem. It is thus imperative that
efforts to integrate data across systems be encouraged
to permit data sharing. In Southern California an ini-
tiative to share patient data across different health
care systems is being tested [49].
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A second barrier is educating patients and equipping
them with tools to manage their health. The health care
delivery systems account for only about 10–20 % of
health outcomes. Most individuals are more often pas-
sive recipients of health care and long-term services and
supports rather than informed, active partners who col-
laboratively make decisions [50]. Health care providers
and health insurers offered fewer than three in ten indi-
viduals electronic or online access to their medical rec-
ord in 2013 [51]. Progression to a patient-centered
health IT infrastructure is recognized as another stra-
tegic goal for the next decade with emphasis on the use
of novel tools. The Blue Button Initiative is one of the
tools developed to enable individuals to securely access,
manage and control their electronic health information
[52] and would be an important tool to allow patients to
have access to their tagged AKI information. The use of
telehealth, virtual medicine and innovative technologies
such as sensors and mobile technology could be a crit-
ical resource to offset the cost and improve compliance
and easiness for longitudinal follow up after AKI.
Thus the informed patient plays a central role in the
longitudinal follow-up after initial AKI episode. The de-
velopment and dissemination of the tools and educa-
tional resources related to AKI to help patients
understand their health information, costs, and care op-
tions and become advocates for their own health is crit-
ical and needs to occur at the time of hospital discharge.
An additional area that needs to be addressed is
provider education and ensuring handoffs to track fol-
low ups. Fewer than 50 % of patients with the most
severe AKI will have a follow-up creatinine measured
within the first three months of hospitalization, and
among AKI survivors with persistent renal dysfunc-
tion at discharge, the referral rates for outpatient
nephrology consultation are as low as 11 % [23, 53].
Since documentation of AKI episode is lacking in dis-
charge summaries for more than half of the patients
and follow up occurs for even fewer patients, it is
plausible to assume that majority of patients with
AKI may never become aware of the diagnosis and
associated risk for adverse long-term outcomes [1, 39,
54, 55]. We propose to set of core required informa-
tion needs to be included at the time of discharge
and that could eventually become core measures that
can be tracked across organizations and linked to
quality of care.
Patients with greater clinical need (and therefore po-
tentially at higher risk of adverse outcomes) are more
likely to be higher users of heath care. This may risk as-
certainment or selection bias [56–58] that can affect
population measurement for some outcomes (e.g. assess-
ment of renal function) more than others (e.g. myocar-
dial infarction, or mortality).
Research questions
 What mechanisms could be utilised to track patients
lost to follow up: e.g., could an AKI tag be recorded
in a central registry similar to a CDC surveillance of
TB or HIV cases?
 Can a minimal data set be used for AKI surveillance
in populations and for development and surveillance
of quality measures?
 Can methods be developed to harmonize data
between patient and population levels, including the
use of data from multiple different sources?
 What approaches or specific therapies are effective
in post AKI care?
 How can methods be developed to stratify patients
into low and high risk of adverse consequences
following AKI; how can this lead to the development
of strategies for individualizing medical care?
Conclusions
The ADQI authors agreed that outcomes following an
episode of AKI should be tracked at both patient and
population levels to allow appropriate patient follow up
and management while concurrently enabling data cap-
ture on the burden and outcomes of AKI. Methodology
to detect and define an episode of AKI must be stan-
dardized using current diagnostic criteria in order to ef-
fectively combine data from multiple sources and
locations. For both patient and population tracking the
patient should be the unit of observation. Relevant clin-
ical information pertaining to an episode of AKI should
be included in a patient’s health care encounter (includ-
ing occurrence and stage of AKI as well as a follow-up
plan). As a minimum follow-up requirement, renal func-
tion and albuminuria should be checked within three
months of an AKI encounter. Currently multiple barriers
for data integration exist at patient, organizational and
national levels. Strategies to tackle these barriers need to
be developed and should include improvements in link-
age between currently fragmented health record systems,
and facilitating patient ownership of relevant medical
information.
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